Financial Performance Forecast - The company expects a net profit attributable to shareholders of RMB 40 million to 48 million for the year 2025, representing a year-on-year decrease of 62.23% to 68.52% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be RMB 26 million to 32 million, reflecting a year-on-year decline of 68.23% to 74.19%[3]. - In 2024, the company reported a total profit of RMB 137.92 million and a net profit attributable to shareholders of RMB 127.07 million[5]. - The financial data in the earnings forecast is preliminary and has not been audited by external accountants[10]. - Investors are advised to pay attention to investment risks as the final financial data will be disclosed in the audited annual report for 2025[11]. R&D and Innovation Strategy - The company maintains a high level of R&D investment to enhance core competitiveness despite the pressure on product prices due to industry-wide procurement policies[7]. - The company emphasizes a long-term operational philosophy focused on leading technology and innovative products to serve human health[9]. - The company is committed to a dual-driven strategy of import substitution and clinical interactive innovation using its proprietary LiCA® technology platform[9]. - The company aims to strengthen cost management and respond proactively to industry changes to build core competitiveness and achieve sustainable high-quality development[9]. Impact of External Factors - The reduction in government subsidies and other non-recurring gains compared to the previous year has impacted the financial performance[9].

Core Viewpoint - The company, Komei Diagnostics, anticipates a significant decline in net profit for the year 2025, projecting a decrease of 62.23% to 68.52% compared to the previous year [1] Financial Projections - The expected net profit for 2025 is estimated to be between RMB 40 million and RMB 48 million [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is projected to be between RMB 26 million and RMB 32 million, reflecting a year-on-year decrease of 68.23% to 74.19% [1] - In 2024, the company reported a net profit of RMB 127 million, with the net profit attributable to the parent company, after deducting non-recurring gains and losses, amounting to RMB 101 million [1]

Group 1 - The core point of the news is that Kemei Diagnostics experienced a stock price increase of 5.18%, reaching 7.72 CNY per share, with a total market capitalization of 3.097 billion CNY as of January 5 [1] - Kemei Diagnostics, established on May 10, 2007, and listed on April 9, 2021, specializes in the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The main revenue composition of Kemei Diagnostics is derived from LiCA series products (93.42%) and CC series products (6.58%) [1] Group 2 - According to data, Penghua Fund has a significant holding in Kemei Diagnostics through its Penghua Quantitative Pioneer Mixed Fund (005632), which held 69,200 shares, accounting for 0.46% of the fund's net value [2] - The Penghua Quantitative Pioneer Mixed Fund has achieved a year-to-date return of 38.28%, ranking 2189 out of 8155 in its category [2] - The fund manager, Shi Yunchao, has been in charge for 1 year and 9 days, with the fund's total asset size at 2.59 billion CNY [3]

Group 1 - The core viewpoint of the news is that Kemei Diagnostics experienced a decline in stock price and trading volume, indicating potential market concerns about its financial performance and investor sentiment [1] - On November 21, Kemei Diagnostics' stock fell by 5.22%, with a trading volume of 53.33 million yuan. The net financing purchase on that day was 471,600 yuan, with a total financing and securities balance of 165 million yuan [1] - The financing balance of Kemei Diagnostics is 165 million yuan, accounting for 5.38% of its circulating market value, which is below the 30th percentile level over the past year, indicating a low financing level [1] Group 2 - As of September 30, Kemei Diagnostics had 10,400 shareholders, a decrease of 0.60% from the previous period, while the average circulating shares per person increased by 0.61% to 38,586 shares [2] - For the period from January to September 2025, Kemei Diagnostics reported operating revenue of 261 million yuan, a year-on-year decrease of 24.13%, and a net profit attributable to shareholders of 41.56 million yuan, down 62.94% year-on-year [2] - Kemei Diagnostics has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

Financial Performance - Total revenue for Q3 2025 was ¥96,206,475.83, a decrease of 18.61% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,221,945.26, down 51.50% year-over-year[3] - The total profit for the year-to-date period decreased by 63.92% to ¥46,155,660.46[3] - Basic earnings per share for Q3 2025 was ¥0.04, a decline of 55.56% compared to the previous year[3] - The company's revenue for the reporting period was CNY 260.82 million, a year-on-year decrease of 24.13%[12] - Net profit attributable to shareholders was CNY 41.56 million, down 62.94% year-on-year[12] - Total operating revenue for the first three quarters of 2025 was CNY 260,821,861.59, a decrease of 24.1% compared to CNY 343,786,670.77 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 41,562,776.02, a decline of 63.0% compared to CNY 112,150,960.47 in the same period of 2024[20] - Operating profit for the first three quarters of 2025 was CNY 45,983,456.08, down 64.0% from CNY 128,141,009.06 in the previous year[20] Research and Development - R&D investment totaled ¥20,744,668.54, representing 21.56% of total revenue, an increase of 4.92 percentage points[4] - The company continues to invest in R&D, focusing on innovative products and technologies to meet clinical needs[12] - Research and development expenses increased to CNY 56,428,488.49 in 2025, up 15.0% from CNY 48,830,331.80 in 2024[20] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥71,178,778.38, down 47.41% year-over-year[3] - Cash and cash equivalents increased to CNY 648.39 million from CNY 400.25 million as of December 31, 2024[15] - Total current assets decreased to CNY 1,030.99 million from CNY 1,067.68 million[15] - The company's cash flow from operating activities for the first three quarters of 2025 showed a significant change, reflecting ongoing adjustments in operational efficiency[22] - Cash inflow from operating activities for the first three quarters of 2025 was $300.41 million, a decrease of 27% compared to $411.58 million in the same period of 2024[23] - Net cash flow from operating activities for the first three quarters of 2025 was $71.18 million, down 47.4% from $135.33 million in 2024[24] - Total assets at the end of the reporting period were ¥1,771,711,225.11, a decrease of 3.30% from the previous year-end[4] - The company's total assets decreased to CNY 1,771,711,225.11 in 2025 from CNY 1,832,158,296.89 in 2024, a reduction of 3.3%[17] Shareholder Information - The top shareholder, Ningbo Free Trade Zone Yingweili Enterprise Management, holds 26.93% of shares[10] - The company maintained a basic and diluted earnings per share of CNY 0.10 for the first three quarters of 2025, down from CNY 0.28 in the same period of 2024[21] Operational Strategy - The company aims to enhance its product pipeline through a dual strategy of import substitution and clinical interaction[12] - The company holds a leading position with its proprietary LICA® technology platform, emphasizing cost-effective clinical products[12] - The company has a robust strategy to address unmet clinical needs and high-burden disease areas[12] Inventory and Costs - The company has maintained a stable inventory level, with inventory reported at CNY 113.82 million[15] - Total operating costs for the first three quarters of 2025 were CNY 223,690,330.27, down from CNY 234,109,060.40 in the previous year, reflecting a reduction of 4.0%[19] Liabilities and Tax - Total liabilities decreased to CNY 363,165,455.02 in 2025 from CNY 415,851,159.52 in 2024, a decline of 12.6%[17] - The company reported cash outflows for tax payments of $31.77 million in 2025, a decrease from $60.59 million in 2024, representing a reduction of 47.5%[24]

Group 1 - Company announced plans to participate in the 2025 semi-annual performance briefing for the medical device and equipment industry on September 17, 2025 [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年9月17日（星期三）下午 15:00-17:00 证券代码：688468 证券简称：科美诊断 公告编号：2025-020 会议召开地点：上海证券交易所上证路演中心 公司于2025年8月30日在上海证券交易所网站（www.sse.com.cn）发布了《 2025年半年度报告》，为便于广大投资者更全面深入地了解公司2025年半年度的 经营成果、财务状况，公司计划于2025年9月17日下午15:00-17:00参加由上海证 券交易所主办的2025年半年度科创板医疗器械及医疗设备行业集体业绩说明会， 就投资者关心的问题进行交流。 一、说明会类型 （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于2025年9月16日（星期二）16:00前通过科美诊断技术股份有限 公司（以下简称"公司"）邮箱ir@chemclin.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答 ...

Group 1 - The core point of the article is the appointment of Mr. Huang Zhengming as the Vice General Manager of Kemei Diagnostics [2][3]

Group 1 - The core point of the article is the appointment of Mr. Li Lin as the new General Manager of Kemei Diagnostics [2][3]